{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:45:58Z","timestamp":1793666758779,"version":"4.5.1"},"reference-count":44,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,5,13]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Evaluate the risks and benefits of upadacitinib 15\u2009mg vs adalimumab in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate based on cardiovascular (CV) risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In SELECT-COMPARE, patients received upadacitinib 15\u2009mg, placebo or adalimumab 40\u2009mg every other week, with background methotrexate. This post hoc analysis assessed patients with lower (age &lt;65 years; no CV risk factors) and higher CV risk (age \u226565 years and\/or \u22651\u2009CV risk factor). Safety and efficacy outcomes were compared between upadacitinib and adalimumab over the short term (~6 months) and long term (5 years) based on CV risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 211 lower-risk patients (upadacitinib, n=129; adalimumab, n=82) and 767 higher-risk patients (upadacitinib, n=522; adalimumab, n=245). Rates of malignancy excluding nonmelanoma skin cancer (NMSC), major adverse cardiovascular event and venous thromboembolism were comparable between upadacitinib and adalimumab in both risk groups but numerically higher in the higher-risk group. Upadacitinib showed higher rates of herpes zoster versus adalimumab in both risk groups and numerically higher rates of serious infection and NMSC in the higher-risk group. Upadacitinib demonstrated consistently better efficacy outcomes, including 28-joint Disease Activity Score (C reactive protein) &lt;2.6, Clinical Disease Activity Index remission and Boolean remission at 6 months, which were generally maintained through 5 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Regardless of baseline CV risk, upadacitinib demonstrated comparable safety to adalimumab, except for higher rates of herpes zoster in both CV risk groups and NMSC and serious infections in the higher-risk group. Upadacitinib consistently showed better clinical and functional outcomes than adalimumab. The benefit\u2013risk profile of upadacitinib in RA patients was favourable, independent of CV risk category, in both short and long term.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-005371","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:19:08Z","timestamp":1749014348000},"page":"e005371","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Benefit\u2013risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02629159","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R","family":"Burmester","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[{"name":"Organizaci\u00f3n M\u00e9dica de Investigaci\u00f3n, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter","family":"Taylor","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hall","sequence":"additional","affiliation":[{"name":"Emeritus Research, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Wick-Urban","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Garrison","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Gao","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Fish","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Strengholt","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"2025090312571935000_11.2.e005371.1","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0014-y","article-title":"Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment","volume":"2","author":"Jagpal","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2025090312571935000_11.2.e005371.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.40"},{"key":"2025090312571935000_11.2.e005371.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2025090312571935000_11.2.e005371.4","unstructured":"Food & Drug Administration . FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"},{"key":"2025090312571935000_11.2.e005371.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2025090312571935000_11.2.e005371.6","unstructured":"[Xeljanz] product information as approved by the CHMP on 10 November 2022, pending endorsement by the European commission. 2022. Available: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/xeljanz-epar-product-information-approved-chmp-10-november-2022-pending-endorsement-european_en.pdf"},{"key":"2025090312571935000_11.2.e005371.7","unstructured":"European Medicines Agency . EMA confirms measures to minimise risk of serious side effects with janus kinase inhibitors for chronic inflammatory disorders 2022. 2022. Available: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic"},{"key":"2025090312571935000_11.2.e005371.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"key":"2025090312571935000_11.2.e005371.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222824"},{"key":"2025090312571935000_11.2.e005371.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221915"},{"key":"2025090312571935000_11.2.e005371.11","first-page":"201","article-title":"Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025090312571935000_11.2.e005371.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"2025090312571935000_11.2.e005371.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"2025090312571935000_11.2.e005371.14","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312571935000_11.2.e005371.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008250"},{"key":"2025090312571935000_11.2.e005371.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"2025090312571935000_11.2.e005371.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00726-8"},{"key":"2025090312571935000_11.2.e005371.18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","article-title":"Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program","volume":"44","author":"Conaghan","year":"2021","journal-title":"Drug Saf"},{"key":"2025090312571935000_11.2.e005371.19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40744-021-00399-5","article-title":"Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis","volume":"9","author":"Conaghan","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025090312571935000_11.2.e005371.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025090312571935000_11.2.e005371.21","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312571935000_11.2.e005371.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(05)80189-X"},{"key":"2025090312571935000_11.2.e005371.23","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2014323"},{"key":"2025090312571935000_11.2.e005371.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez087"},{"key":"2025090312571935000_11.2.e005371.25","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"2025090312571935000_11.2.e005371.26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40744-023-00621-6","article-title":"Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis","volume":"11","author":"Rubbert-Roth","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2025090312571935000_11.2.e005371.27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab447"},{"key":"2025090312571935000_11.2.e005371.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206624"},{"key":"2025090312571935000_11.2.e005371.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2202778"},{"key":"2025090312571935000_11.2.e005371.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223916"},{"key":"2025090312571935000_11.2.e005371.31","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"2025090312571935000_11.2.e005371.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"2025090312571935000_11.2.e005371.33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.therap.2022.04.005","article-title":"Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis","volume":"77","author":"Jalles","year":"2022","journal-title":"Therapie"},{"key":"2025090312571935000_11.2.e005371.34","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02325-9"},{"key":"2025090312571935000_11.2.e005371.35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10067-019-04865-y","article-title":"Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025090312571935000_11.2.e005371.36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2024-eular.1769","article-title":"OP0092\u2005INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS COMPARED TO bDMARDs: FINDINGS FROM AN INTERNATIONAL COLLABORATION OF REGISTERS (THE \u201cJAK-POT\u201d STUDY)","volume":"83","author":"Aymon","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025090312571935000_11.2.e005371.37","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.42846","article-title":"Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients","volume":"76","author":"Charles-Schoeman","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025090312571935000_11.2.e005371.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218419"},{"key":"2025090312571935000_11.2.e005371.39","first-page":"1528","article-title":"Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis","volume":"35","author":"Linde","year":"2008","journal-title":"J Rheumatol"},{"key":"2025090312571935000_11.2.e005371.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01062-9"},{"key":"2025090312571935000_11.2.e005371.41","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0928-y","article-title":"Co-morbidity in patients with early rheumatoid arthritis - inflammation matters","volume":"18","author":"Innala","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312571935000_11.2.e005371.42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes305"},{"key":"2025090312571935000_11.2.e005371.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.07.010"},{"key":"2025090312571935000_11.2.e005371.44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1333995","article-title":"Exploring candidate biomarkers for rheumatoid arthritis through cardiovascular and cardiometabolic serum proteome profiling","volume":"15","author":"Cuesta-L\u00f3pez","year":"2024","journal-title":"Front Immunol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-005371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:57:31Z","timestamp":1756929451000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-005371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,3]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/rmdopen-2024-005371"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-005371","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}